4月16日 - ** 基因治疗公司蓝鸟生物BLUE.O股价盘前下跌8.7%，报4.08美元
** BLUE称，英国私人公司Ayrmid Ltd没有提出有约束力的收购建议， 也没有获得必要的融资
** 该公司在三月份收到了来自 Ayrmid 的非约束性收购要约 (link)，收购金额高达 1.105 亿美元。
** BLUE 补充说，该公司仍面临严重的贷款违约风险。
** 公司董事会重申其支持与凯雷CG.O和SK Capital交易的建议，同时建议所有股东在5月2日前签署当前协议
** BLUE 同意由 Carlyle 和 SK Capital Partners 在 2 月份以折扣价私有化 (link)
** 截至上次收盘，该公司股价已累计下跌 46.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.